Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	172.22	210.78	129.01	-	-	-
Revenue Growth (YoY)	5.74%	63.38%	-	-	-	-
Cost of Revenue	128.77	125.31	99.88	66.61	35.93	-
Gross Profit	43.45	85.48	29.13	-66.61	-35.93	-
Selling, General & Admin	39.34	38.47	32.29	30.64	15.2	5.57
Research & Development	-	-	-	-	-	21.1
Operating Expenses	39.34	38.47	32.29	30.64	15.2	26.67
Operating Income	4.11	47.01	-3.16	-97.25	-51.13	-26.67
Interest & Investment Income	19.7	19.47	15.22	2.63	0.04	0.16
EBT Excluding Unusual Items	23.81	66.49	12.06	-94.62	-51.08	-26.5
Gain (Loss) on Sale of Assets	-	-	-	-	-0.07	-0.02
Pretax Income	23.81	66.49	12.06	-94.62	-51.16	-26.52
Income Tax Expense	-0.97	0.86	18.74	-	-	-
Net Income	24.78	65.63	-6.69	-94.62	-51.16	-26.52
Net Income to Common	24.78	65.63	-6.69	-94.62	-51.16	-26.52
Shares Outstanding (Basic)	39	37	33	31	6	1
Shares Outstanding (Diluted)	41	39	33	31	6	1
Shares Change (YoY)	20.56%	18.01%	5.62%	399.27%	467.09%	18.45%
EPS (Basic)	0.63	1.76	-0.20	-3.02	-8.16	-24.00
EPS (Diluted)	0.61	1.68	-0.20	-3.02	-8.16	-24.00
Free Cash Flow	-58.01	-44.72	134.19	-96.67	-55.44	-27.89
Free Cash Flow Per Share	-1.43	-1.15	4.06	-3.09	-8.85	-25.23
Gross Margin	25.23%	40.55%	22.58%	-	-	-
Operating Margin	2.38%	22.30%	-2.45%	-	-	-
Profit Margin	14.39%	31.14%	-5.18%	-	-	-
Free Cash Flow Margin	-33.68%	-21.21%	104.01%	-	-	-
EBITDA	7.89	50.78	-0.32	-95.35	-50.01	-26.34
EBITDA Margin	4.58%	24.09%	-0.25%	-	-	-
D&A For EBITDA	3.79	3.77	2.84	1.9	1.12	0.33
EBIT	4.11	47.01	-3.16	-97.25	-51.13	-26.67
EBIT Margin	2.38%	22.30%	-2.45%	-	-	-
Effective Tax Rate	-	1.29%	155.45%	-	-	-

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q